Innoviva Q2 2026 revenue up 19%
Innoviva reported Q2 2026 revenue of $119.6 million, increasing 19% year-over-year, driven by its royalty portfolio and net product sales growth from its IST platform. The company also launched Nortiva Bio and announced a licensing agreement with Dr. Reddy's Laboratories.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day